Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I
Status:
Terminated
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
This is a treatment study trial, in which we will assess the safety and tolerability of daily
dose IL-2, as monotherapy for 12 weeks, followed by IL2 in combination with PEG-IFN and RBV
for 48 weeks in the treatment of chronic Hepatitis C.
Phase:
Phase 1
Details
Lead Sponsor:
Weill Medical College of Cornell University
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)